Research and treatment approaches have come a long way since triple-negative breast cancer was first recognised, but there is still progress to be made, according to Associate Prof. Rebecca Dent 

We were hoping to be in Paris for the ESMO Congress 2021, but the event will be virtual for the second consecutive year due to the COVID-19 pandemic. However, this annual Congress will confirm that cancer research is blooming again, despite the current health crisis and its remarkable consequences on people, healthcare system, and, not the least, research

Prof. Lisa Licitra: “Truly pursuing precision medicine means pushing the boundaries of patient selection using molecular biology and artificial intelligence on all big data, not just molecular information” 

Presented at the ESMO Virtual Plenaries this year, four key studies in oncology will animate the debate  

Nearly 1 in 4 patients with pleural malignancy continue to benefit from nivolumab plus ipilimumab at 3 years 

Ensuring equitable access to innovative treatments is now the major challenge in oncology, says Prof. Alex Adjei

Investigations are time-consuming and expensive, so greater public funding is needed, according to Prof. George Coukos